NCT03239340 - A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

September 19, 2023

Study Completion Date

September 19, 2023

Conditions

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.

Trial Locations (26)

10450

Research Site, Pulau Pinang

13620

Research Site, Seongnam

15006

Research Site, A Coruña

20900

Research Site, Monza

25100

Research Site, Brescia

Research Site, Kuantan

28046

Research Site, Madrid

28644

Research Site, Cheongiu

30307

Research Site, Atlanta

30607

Research Site, Athens

35016

Research Site, Las Palmas de Gran Canaria

41009

Research Site, Seville

43126

Research Site, Parma

47014

Research Site, Meldola

47392

Research Site, Busan

59100

Research Site, Lembah Pantai

81100

Research Site, Johor Bahru

93586

Research Site, Kuching

02215

Research Site, Boston

00152

Research Site, Roma

05100

Research Site, Terni

03722

Research Site, Seoul

05505

Research Site, Seoul

06591

Research Site, Seoul

135-710

Research Site, Seoul

08035

Research Site, Barcelona